1 – 10 of 14
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
- [11C]PIB amyloid quantification : effect of reference region selection (
- Amyloid-β PET and CSF in an autopsy-confirmed cohort (
- Test–retest repeatability of [18F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals (
- Why Is Amyloid-β PET Requested After Performing CSF Biomarkers? (
- Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease (
- Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease (
- Combination of plasma amyloid beta(1-42/1-40)and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology (
- 2019
- Discordant amyloid-β PET and CSF biomarkers and its clinical consequences (
- Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum (
- Amyloid-β load is related to worries, but not to severity of cognitive complaints in individuals with subjective cognitive decline : The science project (